Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG).

Conclusions: In advanced ampullary adenocarcinoma, despite higher toxicity, frontline FOLFIRINOX showed a trend toward an OS benefit in the intestinal subtype while providing a similar outcome in the pancreaticobiliary subtype.

also in 53,322 other papers

FOLFIRINOX showed longer survival in this group, with an mOS of 34 months (range, 10–58) compared to gemcitabine-based treatments (13.0, range, 4.5–21.8 months), although it did not reach statistical significance, likely due to the small sample size.

also in 111,027 other papers